New study looks at FDA's use of so­cial me­dia to com­mu­ni­cate on drug safe­ty

A new study look­ing at the FDA use of so­cial me­dia to com­mu­ni­cate about drug safe­ty finds that the agency could im­prove its im­pact by de­vel­op­ing so­cial me­dia strate­gies and tak­ing a more ac­tive role on web plat­forms.

The study, con­duct­ed by re­searchers at Har­vard Med­ical School, North­east­ern Uni­ver­si­ty, Boston Chil­dren’s Hos­pi­tal and The Ohio State Uni­ver­si­ty, and fund­ed by FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search, looks specif­i­cal­ly at FDA’s use of so­cial me­dia fol­low­ing two drug safe­ty com­mu­ni­ca­tions (DSCs) for drugs con­tain­ing zolpi­dem, the ac­tive in­gre­di­ent in Am­bi­en.

In 2013, FDA is­sued two DSCs re­lat­ed to zolpi­dem, the first in Jan­u­ary warn­ing of the risk of next-day im­pair­ment af­ter tak­ing in­som­nia drugs and re­quir­ing low­er rec­om­mend­ed dos­es for drugs con­tain­ing zolpi­dem, and the sec­ond no­ti­fy­ing the pub­lic that the agency had ap­proved those la­bel­ing changes.

In ad­di­tion to pub­lish­ing the DSCs to its web­site, FDA made posts re­lat­ed to the DSCs on its var­i­ous so­cial me­dia ac­counts, in­clud­ing its Face­book page and three of its Twit­ter ac­counts (@US_FDA@FDA_Drug_In­fo and @FDAMed­Watch).

For the first DSC, FDA post­ed once to its Face­book ac­count, get­ting 61 shares, and tweet­ed six times across its three ac­counts, for a to­tal of 111 retweets.

To mea­sure the im­pact of FDA’s posts, the au­thors iden­ti­fied some 174,000 tweets and 59,000 Face­book posts ref­er­enc­ing zolpi­dem be­tween 1 Oc­to­ber 2012 and 31 Au­gust 2013. Of those, rough­ly 9% of the tweets were tagged as ad­verse events (AEs), 74% were tagged as men­tions and 17% were con­sid­ered junk. For the Face­book posts, 5% were iden­ti­fied as AEs, 69% as men­tions and 26% as junk.

How­ev­er, for the sec­ond DSC, FDA did not post to Face­book and on­ly tweet­ed about the DSC for its@FDA_Drug_In­fo ac­count (3 tweets, 37 retweets), though the agency al­so tweet­ed gen­er­al­ly about a group of re­cent pre­scrib­ing changes, in­clud­ing for zolpi­dem, from its@FDAMed­Watch ac­count.

The au­thors ob­served a greater so­cial me­dia re­sponse from both Twit­ter and Face­book users fol­low­ing the first DSC, but did not no­tice an in­crease in so­cial ac­tiv­i­ty re­lat­ed to zolpi­dem fol­low­ing the sec­ond com­mu­ni­ca­tion.

The au­thors say that the dif­fer­ence in so­cial me­dia re­sponse to the two safe­ty com­mu­ni­ca­tions can be ex­plained by the dif­fer­ence in how FDA is­sued the com­mu­ni­ca­tions. In ad­di­tion to post­ing about the first DSC more fre­quent­ly and to more of its ac­counts, the first DSC was al­so is­sued with an ac­com­pa­ny­ing press re­lease.

Rec­om­men­da­tions

To make bet­ter use of its so­cial me­dia pres­ence in the fu­ture, the au­thors rec­om­mend that FDA de­vel­op strate­gies for how and how of­ten to post dif­fer­ent types of mes­sages.

“Since there can be a lot of ques­tion­able in­for­ma­tion shared on so­cial me­dia, the FDA should be able to lever­age its in­de­pen­dent ex­per­tise and po­si­tion as a wide­ly trust­ed source of in­for­ma­tion to help pro­mote ac­cu­rate and in­for­ma­tive mes­sages. In the case of the zolpi­dem safe­ty alerts, the FDA took some steps to do that, but could cre­ate more out­reach and dis­sem­i­nate its ma­te­ri­als more fre­quent­ly via var­ied plat­forms,” Michael Sin­ha, a post­doc­tor­al fel­low at Har­vard and lead au­thor on the pa­per told Fo­cus.

Sin­ha al­so em­pha­sized that the so­cial me­dia land­scape is sub­stan­tial­ly dif­fer­ent now than in 2013 when these safe­ty com­mu­ni­ca­tions were is­sued.

“So­cial me­dia like Twit­ter was seen as more of a recre­ation­al tool in 2013, but now many pro­fes­sion­als, aca­d­e­m­ic in­sti­tu­tions and com­pa­nies have vi­brant so­cial me­dia pres­ences. In­creased health pro­fes­sion­al en­gage­ment on so­cial me­dia in­creas­es the like­li­hood that FDA con­tent on these plat­forms would be more wide­ly dis­sem­i­nat­ed and have a greater im­pact,” he said.

The pa­per al­so rec­om­mends that FDA de­vel­op a greater un­der­stand­ing of so­cial me­dia plat­form fea­tures and user pref­er­ences to de­vel­op its ap­proach to post­ing.

“FDA should try to stay on top of the ever-evolv­ing strate­gies be­ing de­vel­oped on so­cial me­dia to am­pli­fy mes­sages—such as use of han­dles or hash­tags on Twit­ter—that can bring at­ten­tion to im­por­tant drug safe­ty con­tent dis­sem­i­nat­ed by the agency,” Sin­ha said.

The au­thors al­so sug­gest that FDA should take mat­ters in­to its own hands when it comes to up­dat­ing in­for­ma­tion about drugs on Wikipedia.

De­spite mul­ti­ple ed­its to the Wikipedia page cor­re­spond­ing to both com­mu­ni­ca­tions, the pages con­tained in­com­plete in­for­ma­tion and did not cite the DSCs them­selves.

“Giv­en that in­for­ma­tion­al sites like Wikipedia are com­mon­ly ac­cessed by the lay pub­lic for in­for­ma­tion on drugs and that any­one can ed­it the con­tent, the FDA should con­sid­er a plan to for­mal­ly up­date the pages for ap­pro­pri­ate con­tent at the time a DSC is re­leased and to en­sure con­tin­ued ac­cu­ra­cy of the in­for­ma­tion over time,” the au­thors write.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Why it Works: Man­u­fac­tur­ing a Vac­cine in a Mul­ti-Prod­uct Fa­cil­i­ty.

COVID-19 launched the pharmaceutical industry to the frontline in the battle against the fast-spreading global pandemic. The goal: distribute a safe, effective vaccine as quickly as possible. Major players in the vaccine market needed to partner with contract development and manufacturing organizations (CDMOs) to achieve the goal of mass vaccine quantities under expedited timelines. With CDMOs stepping up to play a critical role in the vaccine manufacturing process, multi-product CDMO facilities took the spotlight. Partnerships quickly formed as the race to save lives and fight a pandemic was on.

Merck CEO Rob Davis

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

With rumors swirling about a potential buyout of biotech Acceleron and its lead PAH drug sotatercept, market watchers have been keeping close tabs on industry movers and shakers due up for an expensive bolt-on. According to a new report, it appears Merck may be the one.

Merck is in “advanced talks” on a deal to acquire Cambridge, MA-based Acceleron in what previous reports pegged as a potential $11 billion buyout, the Wall Street Journal reported Monday. A deal could come as early as this week, according to the Journal.

Habib Dable, Acceleron CEO

Days of heat­ed ru­mors cul­mi­nate in a re­port that Ac­celeron is in ad­vanced buy­out talks

Days of frothy rumors about possible M&A discussions at Acceleron were capped late Friday with a Bloomberg report asserting that the biotech company is in advanced talks for an $11 billion buyout deal.

Bloomberg was unable to identify any bidders in the deal, but speculation has been running rampant that the surging value of Acceleron stock had to be the result of leaks around the auction of the company. As of early Monday morning, we’re still awaiting the final word.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.

Alexander Lefterov/Endpoints News

The coro­n­avirus vac­cine that the world for­got could still help save it

Back at the beginning of the pandemic — back when we still called the virus “novel” and a single case in Washington state could make headlines — there emerged the story of the coronavirus vaccine that the world forgot.

It was an allegory for our pandemic ill-preparedness. At a time when the world had been caught so flat-footed, there were a pair of scientists who had seen the crisis coming, lab-coated Cassandras with an antidote if only the world had listened sooner.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ash Shehata, KPMG

As sup­ply chain wor­ries ease up, Big Phar­ma CEOs have a new top con­cern: re­cruit­ing and keep­ing em­ploy­ees

As the industry goes through a boom, Big Pharma’s CEOs seem to have realized one thing above the rest: It’s time to reward the people doing the leg work.

KPMG, a Big Four accounting network, has compiled a business confidence report for pharma CEOs for the past few years, and while 2020’s report had top executives soul-searching for answers and predictions amidst a chaotic time, it appears that some normalcy, coupled with the skyrocketing growth of the industry, has restored confidence levels at the top.

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

As one of the biggest players in an increasingly packed gene therapy space, Pfizer has taken an early lead over specialists like Sarepta in taking a Duchenne muscular dystrophy (DMD) candidate into late-stage testing. But new safety fears have led Pfizer to scale back that trial, cutting out patients with certain genetic mutations.

Pfizer has amended its enrollment protocol for a Phase III test for gene therapy fordadistrogene movaparvovec in DMD after investigators flagged severe side effects tied to specific mutations, according to a letter the drugmaker sent to Parent Project Muscular Dystrophy, a patient advocacy group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.

Kevin Boyle, Ziopharm Oncology CEO

Zio­pharm lays off half its staff af­ter man­u­fac­tur­ing is­sues force de­lays

New Ziopharm CEO Kevin Boyle has only been at the biotech for less than a month, but he’s already engineering major changes.

Late Monday afternoon, Ziopharm announced a sweeping restructuring that involved eliminating more than half its workforce and 60 jobs in total. The layoffs were necessary to help the penny stock player refocus its attention on advancing its TCR program, which saw a setback earlier this year after “unforeseen delays” at a contract manufacturer, Ziopharm said.

Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

Covid-19 roundup: Pfiz­er/BioN­Tech sub­mit vac­cine da­ta to FDA for younger chil­dren; Doc­tors kept pre­scrib­ing hy­drox­y­chloro­quine

Pfizer and BioNTech said Tuesday they submitted to FDA positive data from a Phase II/III trial of their Covid-19 vaccine in children aged 5 to less than 12 years old.

A formal EUA submission for the vaccine in these children is expected to follow “in the coming weeks,” the companies said in a statement.

The trial of 2,268 healthy participants aged 5 to less than 12 years old showed the vaccine was safe and elicited robust neutralizing antibody responses using a two-dose regimen of 10 μg doses, which is one-third the dose that’s administered to adults.

From left to right: Mark Springel, Kristina Wang, Lin Ao, Soufiane Aboulhouda

George Church, his stu­dents, and top VCs go na­tion­wide with a biotech train­ing camp

One night last fall, Floris Engelhardt sat down in her Boston apartment and logged onto a Zoom call, armed with a comic and a vague idea about starting a biotech.

Engelhardt was joining a student-run “match night.” A postdoc at MIT’s Bathe BioNanoLab, where researchers use DNA and RNA like Lego blocks for nanometer-sized structures, Engelhardt wanted to find real-world applications for her work. She sketched out — literally — a plan to use DNA origami, a decade-old technique for precisely folding DNA, to make therapies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.